Topic
Semax
Everything we've written on Semax — 11 articles covering the mechanism, the evidence, comparisons, and practical considerations.
11 articles
Cognitive supportWhat people are reporting about AdamaxThis article summarizes experiences reported in public online communities including Reddit, longevity forums, and discussion boards. We are not advocating human use of any compound discussed here. Many of the peptides discussed are not FDA-approved for the uses described, and some are explicitly not approved for human or veterinary use. What follows is a synthesis of what people have reported, presented to give readers context on the public conversation — not as guidance, not as evidence of safety or efficacy, and not as a recommendation. Decisions about any compound should be made with a qualified prescribing provider after a full medical evaluation.8 min readCognitive supportAdamax — the enhanced Semax analogYou've read the Semax research. The BDNF upregulation is compelling. The Russian clinical data on stroke recovery and cognitive enhancement is more substantial than you expected. The intranasal delivery makes practical sense. And then you get to the pharmacokinetics section and find the number that gives you pause: the half-life of Semax after intranasal administration is measured in minutes. The molecule is active, bioavailable via the olfactory route, and then degraded quickly by peptidases in the blood and tissues. Whatever it's doing, it's doing it briefly, and the dosing implications — multiple administrations per day, careful timing around the desired effect window — are a practical constraint on a compound that's already operating outside the mainstream pharmaceutical supply chain.8 min readOrigins and discoveryThe neuropeptide universe — from Semax and Cortexin to Dihexa, the cognitive enhancement field that doesn't show up in US pharmaIn 1972, a Soviet neuropharmacologist named Nikolai Koval published early research on neuropeptide fragments derived from ACTH — adrenocorticotropic hormone — and their effects on memory and learning in animal models. He was not working in a vacuum. Across Soviet research institutes, the emerging field of neuropeptide biology was being pursued with particular intensity, partly because it offered a theoretical alternative to the receptor-agonist pharmacology dominating Western drug development, and partly because Soviet research programs were structured around different institutional priorities, different funding pressures, and different timelines than their Western counterparts. The compounds that emerged from that tradition — Semax, Selank, Cortexin, Cortagen, Pinealon, and others — are now used clinically in Russia and parts of Eastern Europe. In the United States, most physicians have never heard of them.9 min readOrigins and discoveryPeptide research during the Cold War — the Soviet biology the West didn't seeIn the mid-1970s, in a research institute on Kirochnaya Street in Leningrad, a scientist named Vladimir Khavinson was developing a hypothesis about aging that Western gerontologists would not encounter for another twenty years. The hypothesis was not, at its core, different from ideas circulating in American and European labs about cellular senescence and protein regulation. But the experimental program Khavinson built around it — isolating short peptide fractions from organ tissues and testing them for bioregulatory effects — proceeded in near-total isolation from Western pharmacology, published in Russian-language journals with limited international circulation, funded by the Soviet military through channels that made some of the research formally classified, and shaped by institutional traditions that valued multi-organ systems thinking over the single-target drug development that dominated Western pharmaceutical methodology.10 min readCognitive supportPeptides for cognition — what research has explored for focus, memory, and clarityYou sit down to work and the words on the screen won't stay still in your head. Not because you're tired — you slept. Not because you're distracted — the room is quiet. There's just a layer of gauze between you and the thing you're trying to think through. You reach for a thought and find most of it there, but not all of it. The edges are soft where they used to be sharp.10 min readCognitive supportPeptides for mood and depression — the research landscape beyond conventional antidepressantsIt doesn't always look like what you'd expect. Sometimes it's not the crying or the not getting out of bed. Sometimes it's the months where everything works technically — you show up, you perform, you answer emails — but there's a flatness underneath all of it that doesn't lift. Or it's the anhedonia: the things that used to matter just don't, not in a way you can explain to anyone who hasn't felt it. You mention it to your doctor and the conversation lasts eight minutes, ending with a prescription for an SSRI. You take it, maybe it helps some, maybe it helps enough, maybe it blunts the edges in ways that trade one problem for another. And you wonder, reasonably, whether there's more to understand about what's actually happening and whether there are other directions research has explored.10 min readOrigins and discoveryWhy Russian nootropics never crossed the Atlantic — Semax, Selank, Cortexin, and the regulatory gapSomewhere in a Russian neurological clinic in 1999, a physician is writing a Semax prescription for a patient recovering from ischemic stroke. This is unremarkable in that context — Semax has been an approved pharmaceutical in Russia since 1994, used routinely in neurology wards, prescribed by ordinary physicians for stroke recovery and cognitive decline, with a safety record built across millions of patients. A few thousand miles away, in an American neurologist's office, the same physician has never heard the word. It does not appear in any clinical guideline he was trained on. It does not appear in UpToDate. It does not appear anywhere in the evidence base his institution recognizes as existing.8 min readCognitive supportSemax and Selank — the deeper history of Russian neuropeptide pharmacologyIn the early 1980s, inside a research institute attached to the Russian Academy of Sciences in Moscow, a team of peptide chemists was working on a problem that had preoccupied Soviet pharmacology for decades: how to modify naturally occurring peptide hormones into stable, pharmacologically useful drugs. The Institute of Molecular Genetics was not primarily a clinical institution. It was a molecular biology research center, and its interest in neuropeptides was fundamentally mechanistic — these researchers wanted to understand how small peptide fragments derived from larger hormones could influence brain function in targeted and lasting ways. What they produced, over roughly a decade of synthetic chemistry and biological testing, became Semax and Selank: two synthetic neuropeptides that entered Russian clinical practice in the 1990s and have remained part of the Russian pharmacological landscape ever since.10 min readCognitive supportWhat people are reporting about SemaxThis article summarizes experiences reported in public online communities including Reddit, longevity forums, and discussion boards. We are not advocating human use of any compound discussed here. Many of the peptides discussed are not FDA-approved for the uses described, and some are explicitly not approved for human or veterinary use. What follows is a synthesis of what people have reported, presented to give readers context on the public conversation — not as guidance, not as evidence of safety or efficacy, and not as a recommendation. Decisions about any compound should be made with a qualified prescribing provider after a full medical evaluation.8 min readCognitive supportSemax, Selank, and the calm-focus questionYou've tried the stimulant route. The first week was productive — maybe genuinely productive — and then the jitteriness settled in, the appetite disappeared, and the crash at 4 p.m. made the second half of the day feel like a tax you owed. You've tried the other route too: the SSRI that took the edge off everything, including the part of you that cared about getting things done. Somewhere between wired and flat there's a thing you're looking for, and it doesn't seem to have a name.8 min readCognitive supportThe mood that's flat, not sad — when depression doesn't quite fitYou're not sad exactly. There's no event that explains it, no loss you're processing, no acute thing you can point to and say: that's why. Life is fine by every external measure — the job functions, the relationships are intact, there's nothing wrong. But somewhere in the last year or two, color has gone out of things. The meal at the restaurant you've been wanting to try is good but it doesn't quite land the way a meal like that used to. Music that used to move you plays and you register that it's good without feeling it. You accomplish something you worked toward and there's a moment of mild satisfaction that doesn't build to anything. Sex happens but the wanting is muted. You're going through the motions of a life that still works but you're not quite inside it.8 min read